183 related articles for article (PubMed ID: 25967462)
1. Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis.
Luengo-Gil G; González-Billalabeitia E; Chaves-Benito A; García Martínez E; García Garre E; Vicente V; Ayala de la Peña F
Breast Cancer Res Treat; 2015 Jun; 151(3):577-87. PubMed ID: 25967462
[TBL] [Abstract][Full Text] [Related]
2. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems.
Choi M; Park YH; Ahn JS; Im YH; Nam SJ; Cho SY; Cho EY
Breast Cancer Res Treat; 2016 Dec; 160(3):475-489. PubMed ID: 27730423
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic role of miR-20a in breast cancer.
Luengo-Gil G; Gonzalez-Billalabeitia E; Perez-Henarejos SA; Navarro Manzano E; Chaves-Benito A; Garcia-Martinez E; Garcia-Garre E; Vicente V; Ayala de la Peña F
PLoS One; 2018; 13(4):e0194638. PubMed ID: 29617404
[TBL] [Abstract][Full Text] [Related]
5. From clinical trials to clinical practice: outcome of NSABP-B27 neoadjuvant chemotherapy regimen for high-risk early-stage breast cancer.
Abdel-Razeq H; Marei L; Saadeh SS; Abdulelah H; Abu-Nasser M; Salam M; Daana W; Al-Haj Ali B; Taqash A
Breast Cancer Res Treat; 2017 Oct; 165(3):771-777. PubMed ID: 28667456
[TBL] [Abstract][Full Text] [Related]
6. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.
Tolaney SM; Boucher Y; Duda DG; Martin JD; Seano G; Ancukiewicz M; Barry WT; Goel S; Lahdenrata J; Isakoff SJ; Yeh ED; Jain SR; Golshan M; Brock J; Snuderl M; Winer EP; Krop IE; Jain RK
Proc Natl Acad Sci U S A; 2015 Nov; 112(46):14325-30. PubMed ID: 26578779
[TBL] [Abstract][Full Text] [Related]
7. Circulating HOTAIR expression predicts the clinical response to neoadjuvant chemotherapy in patients with breast cancer.
Lu R; Zhang J; Zhang W; Huang Y; Wang N; Zhang Q; Qu S
Cancer Biomark; 2018; 22(2):249-256. PubMed ID: 29630518
[TBL] [Abstract][Full Text] [Related]
8. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
Spring L; Greenup R; Niemierko A; Schapira L; Haddad S; Jimenez R; Coopey S; Taghian A; Hughes KS; Isakoff SJ; Ellisen LW; Smith BL; Specht M; Moy B; Bardia A
J Natl Compr Canc Netw; 2017 Oct; 15(10):1216-1223. PubMed ID: 28982747
[No Abstract] [Full Text] [Related]
9. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
Dong T; Kang X; Liu Z; Zhao S; Ma W; Xuan Q; Liu H; Wang Z; Zhang Q
Tumour Biol; 2016 Jun; 37(6):8159-68. PubMed ID: 26715276
[TBL] [Abstract][Full Text] [Related]
10. Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade.
Hennigs A; Riedel F; Marmé F; Sinn P; Lindel K; Gondos A; Smetanay K; Golatta M; Sohn C; Schuetz F; Heil J; Schneeweiss A
Breast Cancer Res Treat; 2016 Dec; 160(3):491-499. PubMed ID: 27744486
[TBL] [Abstract][Full Text] [Related]
11. On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer.
Bownes RJ; Turnbull AK; Martinez-Perez C; Cameron DA; Sims AH; Oikonomidou O
Breast Cancer Res; 2019 Jun; 21(1):73. PubMed ID: 31200764
[TBL] [Abstract][Full Text] [Related]
12. Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer.
Krüger K; Silwal-Pandit L; Wik E; Straume O; Stefansson IM; Borgen E; Garred Ø; Naume B; Engebraaten O; Akslen LA
Sci Rep; 2021 Feb; 11(1):3388. PubMed ID: 33564016
[TBL] [Abstract][Full Text] [Related]
13. Long-term Results After Neoadjuvant Chemotherapy for Breast Cancer: A Single-center Experience.
Giani M; Renda I; Vallario A; Tavella K; Villanucci A; Nori J; Vanzi E; Bianchi S; Susini T
Anticancer Res; 2020 Feb; 40(2):1079-1085. PubMed ID: 32014957
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated macrophages in human breast cancer parenchyma negatively correlate with lymphatic metastasis after neoadjuvant chemotherapy.
Mitrofanova I; Zavyalova M; Telegina N; Buldakov M; Riabov V; Cherdyntseva N; Kzhyshkowska J
Immunobiology; 2017 Jan; 222(1):101-109. PubMed ID: 27510849
[TBL] [Abstract][Full Text] [Related]
15. High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer.
Wang T; Srivastava S; Hartman M; Buhari SA; Chan CW; Iau P; Khin LW; Wong A; Tan SH; Goh BC; Lee SC
Oncotarget; 2016 Aug; 7(34):55155-55168. PubMed ID: 27487140
[TBL] [Abstract][Full Text] [Related]
16. Plasma fibrinogen level may be a possible marker for the clinical response and prognosis of patients with breast cancer receiving neoadjuvant chemotherapy.
Mei Y; Liu H; Sun X; Li X; Zhao S; Ma R
Tumour Biol; 2017 Jun; 39(6):1010428317700002. PubMed ID: 28621233
[TBL] [Abstract][Full Text] [Related]
17. The effect of neoadjuvant chemotherapy on the correlation of tumor-associated macrophages with CD31 and LYVE-1.
Mitrofanova I; Zavyalova M; Riabov V; Cherdyntseva N; Kzhyshkowska J
Immunobiology; 2018; 223(6-7):449-459. PubMed ID: 29459011
[TBL] [Abstract][Full Text] [Related]
18. Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis.
García Garre E; Luengo Gil G; Montoro García S; Gonzalez Billalabeitia E; Zafra Poves M; García Martinez E; Roldán Schilling V; Navarro Manzano E; Ivars Rubio A; Lip GYH; Ayala de la Peña F
Breast Cancer Res Treat; 2018 May; 169(1):83-92. PubMed ID: 29340882
[TBL] [Abstract][Full Text] [Related]
19. Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations.
Höglander EK; Nord S; Wedge DC; Lingjærde OC; Silwal-Pandit L; Gythfeldt HV; Vollan HKM; Fleischer T; Krohn M; Schlitchting E; Borgen E; Garred Ø; Holmen MM; Wist E; Naume B; Van Loo P; Børresen-Dale AL; Engebraaten O; Kristensen V
Genome Med; 2018 Nov; 10(1):92. PubMed ID: 30497530
[TBL] [Abstract][Full Text] [Related]
20. Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer.
Xue MQ; Liu J; Sang JF; Su L; Yao YZ
Oncotarget; 2017 Jul; 8(30):48930-48937. PubMed ID: 28454081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
